Page last updated: 2024-08-24

gemcitabine and ci 994

gemcitabine has been researched along with ci 994 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Albella, B; Bueren, JA; Keyes, KA; LoRusso, PM; Parchment, RE	1
Albella, B; Bueren, JA; Keyes, KA; Parchment, RE; Segovia, JC	1
Boehm, KA; Clark, M; Dasse, KD; Grove, W; Gulyas, S; Krishnamurthi, SS; Macdonald, K; Richards, DA; Rosemurgy, A; Wagener, DJ; Waterhouse, DM	1

Trials

1 trial(s) available for gemcitabine and ci 994

Article	Year
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:7 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phenylenediamines; Prognosis; Survival Rate	2006

Article

Year

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.

Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:7

Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phenylenediamines; Prognosis; Survival Rate

2006

Other Studies

2 other study(ies) available for gemcitabine and ci 994

Article	Year
Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:6 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Blood Cell Count; Blood Platelets; Bone Marrow; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Melphalan; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neutropenia; Neutrophils; Phenylenediamines; Random Allocation; Stem Cells; Time Factors	2000
Latent hematopoietic stem cell toxicity associated with protracted drug administration. Experimental hematology, 2001, Volume: 29, Issue:3 Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Bone Marrow; Colony-Forming Units Assay; Crosses, Genetic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematopoiesis; Hematopoietic Stem Cells; Injections, Intraperitoneal; Male; Melphalan; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Phenylenediamines; Time Factors	2001

Article

Year

Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:6

Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Blood Cell Count; Blood Platelets; Bone Marrow; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Melphalan; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neutropenia; Neutrophils; Phenylenediamines; Random Allocation; Stem Cells; Time Factors

2000

Latent hematopoietic stem cell toxicity associated with protracted drug administration.

Experimental hematology, 2001, Volume: 29, Issue:3

Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Bone Marrow; Colony-Forming Units Assay; Crosses, Genetic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematopoiesis; Hematopoietic Stem Cells; Injections, Intraperitoneal; Male; Melphalan; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Phenylenediamines; Time Factors

2001